SBIR/STTR Research Award

NOVEL RED FLUOROPHORE FOR MULTIPLE MRNA TARGET DETECTION

Award identifier ad7dd750778c77415affdc406966e2e45e4600c2f6e55c27b74fbb290a3c579dAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$100,000

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CHROMAGEN, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR application is to develop novel red fluorophores with large Stokes' shift and high quantum yield. Chromagen has already developed two novel fluorophores with trade names StarBright Green and StarBright Orange. The long-term objective of the proposal (Phase II) is to utilize the novel red fluorophores in gene expression assays to detect multiple messenger RNA (mRNA) targets in a high throughput screening (HTS) format for pharmaceutical drug discovery. Such an oligonucleotide based, simultaneous multi-target detection system will greatly facilitate monitoring expression of genes involved in cancer and other diseases and drug discovery that requires a high throughput screening format. The technological innovation of the proposed research lies in the novel design and successful synthesis of a series of polycyclic aromatic compounds which will result in red fluorescent dyes that possess photo-stability, high quantum yields, and large Stokes' shifts. Developing inexpensive, fast, facile and ultrasensitive multi-target gene expression assays will contribute to the technological advancement of molecular research and clinical diagnostics. This will be a proposal for a Phase II grant application. Chromagen has already demonstrated its ability to develop assays to detect two targets in the same micro-well in a high throughput screening format. Developing a triple target gene expression assay will not only enhance the gene discovery process, but will also expedite the identification of lead drug candidates in the pharmaceutical industry. PROPOSED COMMERCIAL APPLICATION: An ultra-sensitive, photostable red fluorophore with large Stokes-Shift will have tremendous commercial applications in Flow-Cytometry, In-Situ Hybridization, Nucleic Acid-based Hybridization.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.